Remove 2006 Remove Licensing Remove Pharmacy Remove Research
article thumbnail

NOW AVAILABLE: The 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Drug Channels

Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Pharmacies and Pharmacy Benefit Managers , our 13th edition, provides a comprehensive, fact-based, and non-partisan tool for understanding the entire U.S. Copyright © 2006-2022 Pembroke Consulting, Inc.

article thumbnail

NOW AVAILABLE: The 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Drug Channels

reviews the evolving specialty pharmacy industry and discusses emerging challenges from direct distribution models that bypass wholesale distribution. We provide updated, expanded, and reorganized data about the following markets: Pharmacy services administrative organizations (Section 2.2.4.) and Section 6.4.3. A new Section 6.2.2.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Dobbs Would Likely Have Significant Impacts On Drug And Device Companies

Drug & Device Law

Even with some attempt to “stay in our lane,” we can see significant impacts on the legal framework in which a number of medical product manufacturers, to say nothing of distributors, pharmacies, and healthcare providers, operate. This is not a matter of us injecting our personal and political views into areas we do not belong.

article thumbnail

The FDA and Feasible Alternative Designs

Drug & Device Law

Without an FDA license to produce another design, [defendant] was legally prohibited from distributing either [alternative design advocated by plaintiffs] at the time [plaintiff] received her vaccinations. 2006), app. In at least the short term, a popular pain reliever would have to be removed from pharmacies. 2d 397 (6th Cir.

FDA 59